Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.

Autor:	Mahmud R; Department of Neurology, Dhaka Medical College, Dhaka, Bangladesh., Rahman MM; Department of Medicine, Dhaka Medical College Hospital, Dhaka, Bangladesh., Alam I; Department of Neurology, Dhaka Medical College, Dhaka, Bangladesh., Ahmed KGU; Department of Neurology, Dhaka Medical College, Dhaka, Bangladesh., Kabir AKMH; Department of Medicine, Dhaka Medical College Hospital, Dhaka, Bangladesh., Sayeed SKJB; Department of Medicine, Dhaka Medical College Hospital, Dhaka, Bangladesh., Rassel MA; Department of Neurology, Dhaka Medical College, Dhaka, Bangladesh., Monayem FB; Sarkari Karmachari Hospital, Dhaka, Bangladesh., Islam MS; Sarkari Karmachari Hospital, Dhaka, Bangladesh., Islam MM; Ministry of Health Family Welfare, Dhaka, Bangladesh., Barshan AD; Department of Medicine, Dhaka Medical College Hospital, Dhaka, Bangladesh., Hoque MM; Department of Medicine, Dhaka Medical College Hospital, Dhaka, Bangladesh., Mallik MU; Department of Medicine, Dhaka Medical College Hospital, Dhaka, Bangladesh., Yusuf MA; Department of Microbiology, National Institute of Neurosciences and Hospital, Dhaka, Bangladesh., Hossain MZ; Department of Medicine, Dhaka Medical College Hospital, Dhaka, Bangladesh.
Jazyk:	angličtina
Zdroj:	The Journal of international medical research [J Int Med Res] 2021 May; Vol. 49 (5), pp. 3000605211013550.
DOI:	10.1177/03000605211013550
Abstrakt:	Objective: We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection. Methods: This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups. The primary outcome was duration from treatment to clinical recovery. Secondary outcomes were disease progression and persistent COVID-19 positivity by RT-PCR. Results: Among 556 screened patients, 400 were enrolled and 363 completed follow-up. The mean patient age was 40 years, and 59% were men. The median recovery time was 7 (4-10, treatment group) and 9 (5-12, placebo group) days (hazard ratio, 0.73; 95% confidence interval, 0.60-0.90). The number of patients with a ≤7-day recovery was 61% (treatment group) and 44% (placebo groups) (hazard ratio, 0.06; 95% confidence interval, 0.04-0.09). The proportion of patients who remained RT-PCR positive on day 14 and whose disease did not progress was significantly lower in the treatment group than in the placebo group. Conclusions: Patients with mild-to-moderate COVID-19 infection treated with ivermectin plus doxycycline recovered earlier, were less likely to progress to more serious disease, and were more likely to be COVID-19 negative by RT-PCR on day 14. Trial Registration: ClinicalTrials.gov Identifier: NCT04523831. Data Repository Id: Dryad. doi:10.5061/dryad.qjq2bvqf6.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu